Molecular and clinical genetics
In September 1989 Tsui, Collins, and Riordan described the AF508 mutation of the cystic fibrosis gene. Since then a "gene consortium" of over 20 laboratories under the direction of Dr Tsui have shared information and gene probes. These groups have described over 60 mutations of the gene, which include other base triplet deletions and mis-sense and nonsense changes that often result in truncation of the transmembrane regulator protein that is defective in cystic fibrosis (known as the cystic fibrosis transmembrane regulator protein The implications of the already large and increasing number of known mutations of the cystic fibrosis gene for family and population screening were discussed. There is considerable racial variation in the occurrence of mutations. For example, the proportion of cases caused by a F508 was reported to increase from 40% to 85% between south east and north west Europe. In North America this mutation is common in some ethnic groups, such as the Amish and Hutterites, but relatively uncommon in Ashkenazi Jews. These racial variations and the large number of rare mutations raise the question of how many mutations should be screened for in a particular population. Screening for a few would result in a relative rather than an absolute risk for a given pregnancy, and it was proposed that for any population a 90-95% predictive ability is necessary to justify a population based screening programme. This may be possible in Britain by screening for three to five mutations, as AF508 is present in 75-80% of patients with cystic fibrosis. Some pilot experience of population screening was reported from a study based on general practices in southern England. Eighty five per cent of adults of reproductive age offered screening through their family doctor or family planning clinic had little or no knowledge of the nature of cystic fibrosis. The best uptake of screening occurred in patients who were opportunistically offered the screening test when attending their general practitioner, local baby clinic, or family planning clinic for other reasons. Disappointingly, less than 20% responded to a letter inviting them to attend for a screening test. Less than 40% of all the women screened said that they would definitely have a termination of their pregnancy if found to be carrying an affected fetus. These results raise the question of whether population screening will be logistically feasible, cost effective, and acceptable to the general public. The effect of litigation, particularly in the United States, may be a further complication.
Structure and function of the cystic fibrosis transmembrane regulator
The structure and function of the gene product, the cystic fibrosis transmembrane regulator protein, is still not elucidated. Chloride ion transport in cystic fibrosis epithelium has been known for some years to be abnormal and when the protein was sequenced it seemed possible that it might be an active chloride transporter. The evidence, 
Lung disease
The sessions devoted to lung disease focused on mechanisms of injury, particularly in the context of Pseudomonas aeruginosa infection. The importance of neutrophil recruitment and the subsequent imbalance of the elastaseantielastase ratio in the lung were considered.
The possible use of antiproteases, such as a, antiproteinase, or a secretory leucoprotease inhibitor to reduce elastase activity were discussed. In an open study of 12 patients with cystic fibrosis nebulised recombinant ax, antiproteinase treatment for seven days resulted in a reduction in the purulence and volume of sputum and an improvement in spirometric values and gas transfer. Further studies will be necessary but these compounds are likely to be helpful in managing lung disease in cystic fibrosis. Other systemic anti-inflammatory treatments were suggested. The role of steroids and non-steroidal anti-inflammatory agents are currently under investigation but no firm evidence was presented to support their use. One small though controlled study suggested that hospital admissions with respiratory exacerbation were reduced with regular treatment with the non-steroidal anti-inflammatory drug piroxicam.
The role of inflammatory cytokines such as tumour necrosis factor alpha and interleukins 1 and 6 was also discussed and some evidence was advanced to suggest that they might be important in mediating pulmonary inflammation in cystic fibrosis. These cytokines may perpetuate the chronic inflammatory response, causing further lung damage, and they may contribute to the progressive weight loss seen in the later stages of disease. Regulation of the cytokine network was suggested as a potentially useful approach that might attenuate local inflammatory processes and reduce lung damage.
Nutrition and energy
Few new developments in nutritional support were reported. The importance of accurate assessment ofnutritional state was emphasised, though most centres will not be able to undertake detailed measurements ofmetabolic rate as suggested. Although resting energy expenditure is raised in cystic fibrosis, total daily energy expenditure was reported to be similar to that of control subjects. Patients with cystic fibrosis have a reduced level of daily activity to compensate for their increased resting metabolic rate. Diabetes and hepatic complications were also discussed but no important developments in these areas were reported.
Many nursing, paramedical, psychological, and social issues were discussed and these sessions were particularly helpful for the many non-clinical care givers attending the conference. An increasing enthusiasm was evident among nurses and others for critically evaluating their practice. This first major conference after the discovery of the gene was stimulating and challenging. Many questions on the function of the cystic fibrosis transmembrane regulator, the application of gene therapy, and the role, if any, of population screening have yet to be answered. A gene therapy cure for the membrane defect is at least five and maybe 10 years away, but it is encouraging and exciting to know that the membrane defect can be corrected in vitro. In the meantime there is much to be done in caring for those patients who have already substantial lung disease and ways to minimise lung damage must be actively pursued.
